

# Review Week: Promoting Cross-Functional Collaboration during Study Start-up



Beth Scanlan, MAP, CCRP; Aaron Holley, BS, CCRP; Cindy Jones MSN, RNP-BC, CCRP;  
Matthew Kovak, MS, CCRP; Michael Birrer, MD  
Cancer Clinical Trials Office, Winthrop P. Rockefeller Cancer Institute,  
University of Arkansas for Medical Sciences

## Background

The process for clinical trial start-up is complex and involves efforts of many different teams within the Clinical Trials Office (CTO). Previous attempts to convene a single, extended duration meeting at the beginning of the start-up process fell short. The previous method resulted in lack of preparedness, inadequate discussion and protocol understanding, which led to scheduling delays and lack of communication regarding follow-up responsibility. A streamlined process was necessary to shorten the study activation timeline while allowing for cross-functional collaboration across all disciplines of the study team.

## Goals

- Decrease study start-up time
- Efficiently negotiate the budget based on required clinical treatment plan
- Streamline development of the clinical treatment plan and billing procedures
- Maximize cross-functional collaboration across study teams and study sponsor/Contract Research Organization (CRO)

## Methods

The CTO implemented a process to include the addition of a Review Week during the early stages of the study start-up process. The Regulatory Specialist (RS) assigned to the study is responsible for uploading pertinent documents into a shared file prior to the week. The RS is responsible for scheduling and leading the Review Week, taking minutes, and corresponding with the sponsor/CRO and Principal Investigator regarding issues that require attention. Attendees include staff from Finance, Coverage, and Clinical teams within the CTO as well as a representative from the Research Pharmacy. The week consists of daily, virtual meetings that provide opportunity for study staff to review the budget build and discuss aspects of the protocol and treatment plan. During the thirty-minute meetings, the teams review the protocol for clinical, financial, and regulatory questions. Internal clinical workflows and processes are discussed and assessed to minimize logistical issues as compared to current standard of care practices. Daily meetings provide opportunity to correspond with the sponsor/CRO to resolve questions that arise and report back later in the week with resolutions. The RS distributes minutes daily including an outline of questions and topics to be resolved during the week.

## Outcomes

- ☑ Increased collaborative work across teams
- ☑ Increased efficiency and staff engagement
- ☑ Quicker clinical review, Beacon validation, EMR activation
- ☑ Decreased start-up timelines by an average of twenty-two days, while simultaneously more than doubling the number of studies activated yearly

## Future Directions

- Designating a start-up specific team
- Developing templates to be used by teams to make sure common, critical questions are answered in advance
- Developing a checklist for the Regulatory Specialist incorporating topics that are generally addressed

## Contact

**Aaron Holley, CCRP**  
**Regulatory Manager**  
Cancer Clinical Trials Office  
University of Arkansas for Medical Sciences  
4301 West Markham, Slot 724  
Little Rock, AR 72205  
(501) 686-8274; jaholley@uams.edu